UroGen's Chief Medical Officer Sells $400K in Stock Following Significant Share Price Increase

Mark Schoenberg, UroGen Pharma Ltd.'s (NASDAQ:URGN) Chief Medical Officer, sold $400,000 worth of shares on July 9, 2026. The sale was conducted under a pre-established Rule 10b5-1 trading plan and marked the conclusion of that schedule. Schoenberg still holds over $4.8 million in company stock.

By Jonathan Ponciano, The Motley Fool Sun, July 12, 2026 at 9:31 PM GMT+3 4 min read · Yahoo Finance · July 12, 2026, 18:31 UTC

Tickers: $URGN

Topics: biotech SEC filings stock_sales

Read the full article at Yahoo Finance

More World news

Donald Trump Jr. Steps Down from Kalshi Advisory Role Due to Conflict of Interest CNBC · November 12, 2026, 19:14 UTC
Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC